Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2012, Article ID 217185, 7 pages
http://dx.doi.org/10.1155/2012/217185
Review Article

Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy

Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA

Received 15 July 2011; Accepted 15 September 2011

Academic Editor: Quyen D. Chu

Copyright © 2012 Parvin F. Peddi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Triple negative breast cancer is an aggressive form of breast cancer with limited treatment options and is without proven targeted therapy. Understanding the molecular basis of triple negative breast cancer is crucial for effective new drug development. Recent genomewide gene expression and DNA sequencing studies indicate that this cancer type is composed of a molecularly heterogeneous group of diseases that carry multiple somatic mutations and genomic structural changes. These findings have implications for therapeutic target identification and the design of future clinical trials for this aggressive group of breast cancer.